We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
PARP inhibitors as a radiosensitizer: a future promising approach in prostate cancer?
- Authors
Angel, Martin; Zarba, Martin; Sade, Juan Pablo
- Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors (iPARPs) have shown efficacy in homologous recombination (HR) deficiency patients with advanced castration resistant prostate cancer and have shown a radiosensitizing effect in preclinical and early clinical trials. Preclinical data in prostate cancer cells suggest a similar cytotoxic effect with half the radiation dose under the effect of Olaparib or Rucaparib irrespective of HR status. Due to the biologic synergy of radiotherapy (RT) and iPARPs, the risk of recurrence of high-risk prostate cancer and the morbidity associated with prostate cancer local treatment, this interesting strategy seems promising, and a better understanding of the clinical implications remains to be elucidated.
- Subjects
CASTRATION-resistant prostate cancer; PROSTATE cancer; POLY(ADP-ribose) polymerase; PROSTATE-specific antigen; POLY ADP ribose
- Publication
Ecancermedicalscience, 2021, Vol 15, Issue 1316-1337, p1
- ISSN
1754-6605
- Publication type
Article
- DOI
10.3332/ecancer.2021.ed118